Biotech Updates

Europe Grants CRISPR-Cas9 Patent to Calyxt

December 19, 2018

A patent has been issued by the European Patent Office to Calyxt, Inc. which gives them permission to create gene-edited plants by the transient delivery of sequence-specific nucleases, including CRISPR-Cas9.

"Conventionally, gene editing is performed by delivering DNA to cells," says Dr. Dan Voytas, Calyxt's Chief Science Officer and University of Minnesota Professor. "The DNA encodes a nuclease, such as CRISPR-Cas9, which makes the gene edit. The problem with conventional gene editing is that DNA can integrate randomly into the genome, creating off-target effects. For example, genes can be disrupted by the incoming DNA that you didn't intend to disrupt. Calyxt has accomplished a precise method of gene editing that creates plants with the desired traits."

Calyxt has been using TALENĀ® in developing  better food products, but the company is continuously trying out new gene editing technologies and approaches to edit plant genes. Calyxt's intellectual property portfolio is also strengthened by having licensed from Cellectis two patents of a family claiming the uses of chimeric nucleases, such as TALENĀ® and CRISPR-Cas9, for gene editing in any type of cells.

Read the media release from Calyxt.